Biofrontera AG Logo

Biofrontera AG

Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.

B8F | F

Overview

Corporate Details

ISIN(s):
DE000A409625 (+2 more)
LEI:
391200D6GFSVFGFQTL13
Country:
Germany
Address:
Hemmelrather Weg 201, 51377 Leverkusen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The company focuses on innovative products for the care, protection, and treatment of skin conditions. Its core expertise is in photodynamic therapy (PDT), offering a combination of its prescription drug, Ameluz®, and its medical device, the RhodoLED® lamp, primarily for the treatment of actinic keratosis. The company's portfolio also includes topical antibiotics and other medical cosmetic products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-10 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.3 KB
2025-05-13 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 205.3 KB
2025-05-09 00:00
Regulatory News Service
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 138.8 KB
2025-04-17 15:05
Pre-Annual General Meeting Information
Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.20…
German 44.5 KB
2025-04-17 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 14.04.2025 bis zum 13.04.2029
German 6.5 KB
2024-09-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2024 bis zum 30.06…
German 264.3 KB
2024-09-26 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-07-21 00:00
Legal Proceedings Report
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
German 11.8 KB
2024-05-02 00:00
Regulatory News Service
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 132.6 KB
2024-05-02 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 185.6 KB
2024-04-29 00:00
Annual Report
English 4.0 MB
2024-04-24 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.3 KB
2023-08-31 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
German 236.4 KB
2023-08-18 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2023-05-02 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 539.4 KB

Automate Your Workflow. Get a real-time feed of all Biofrontera AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biofrontera AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biofrontera AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-03-24 Deutsche Balaton Aktiengesellschaft Close relation Buy None 7,366.00 EUR
2023-03-24 Deutsche Balaton Aktiengesellschaft Close relation Buy None 381.00 EUR
2023-03-20 Deutsche Balaton Aktiengesellschaft Close relation Buy None 7,503.16 EUR
2023-03-13 NEON Equity AG Close relation Buy None 30,627.00 EUR
2023-03-13 Deutsche Balaton Aktiengesellschaft Close relation Buy None 6,290.31 EUR
2023-03-13 Deutsche Balaton Aktiengesellschaft Close relation Buy None 635.00 EUR
2023-03-13 TO Holding 1 GmbH Close relation Buy None 575.00 EUR
2023-03-10 Deutsche Balaton Aktiengesellschaft Close relation Buy None 6,718.30 EUR
2023-03-08 Adenauer, Dr. Sven-Georg Other Buy None 140,000.00 EUR
2023-03-06 Deutsche Balaton Aktiengesellschaft Close relation Buy None 152.40 EUR

Peer Companies

Tango Therapeutics, Inc. Logo
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America
TNGX
Tarsus Pharmaceuticals, Inc. Logo
Develops novel therapies for eye care, including the first FDA-approved Demodex blepharitis drug.
United States of America
TARS
TAUNS Laboratories, Inc. Logo
Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.
Japan
197A
Taysha Gene Therapies, Inc. Logo
Developing AAV-based gene therapies for rare, severe monogenic diseases of the central nervous system.
United States of America
TSHA
Tchaikapharma High Quality Medicines AD Logo
Develops and makes affordable generic drugs for cardiovascular & metabolic diseases.
Bulgaria
THQM
TDSPHARM Co., Ltd. Logo
Develops and manufactures transdermal drug delivery systems like patches, plasters, and OTC products.
South Korea
464280
Tectonic Therapeutic, Inc. Logo
Developing biologic therapies that modulate GPCRs for diseases with unmet needs.
United States of America
TECX
Tego Science, Inc. Logo
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
South Korea
191420
Develops radiopharmaceuticals that use targeted radiation to image and treat various cancers.
United States of America
TLX
Telomir Pharmaceuticals, Inc. Logo
Developing an oral small molecule to reverse aging and treat age-related diseases.
United States of America
TELO

Talk to a Data Expert

Have a question? We'll get back to you promptly.